European patent granted to ASIT biotech

ASIT biotech announces the grant of a European patent on the active ingredients used in the ASIT+ allergy immunotherapy product candidates

ASIT biotech, a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialisation of breakthrough immunotherapy products for the treatment of allergies, announced the European Patent Office has granted a patent covering the active ingredients used in the ASIT+ allergy immunotherapy products candidates for pollen, mite and food allergies.

The grant will be effective from 1 November, 2017 until 28 June, 2027 with a possible extension of 5 years via a supplementary protection certificate.

The corresponding patents are already granted in China, Japan and India. Patent prosecutions for the grants of the corresponding patents in the USA and Brazil are ongoing.

Thierry LEGON, CEO of ASIT biotech, said: “The grant of this patent in Europe is a major milestone in the protection of our assets as well as a recognition that our products are unique and innovative. Europe is currently the biggest market of allergy immunotherapy products in the world. Therefore, the long-term protection conferred by this patent in Europe is of high strategic importance.”

Companies